HER-2 mutation

Brilliant lectures on RAS mutations, HER2 alterations and Claudin 18.2 overexpression in gastrointestinal cancers #WCGIC2023 (@carlosbon78)

Findings from a subgroup analysis of the phase 3 EMERALD trial demonstrated elacestrant elicited prolonged PFS vs SOC in ER+, HER2– non-detected ESR1 mutated breast cancer who experienced disease progression. @VKaklamani #ASCO23 #bcsm https://t.co/lPcacbcFRo (@OncLive)

Hot off the press from @ASCO #TAPUR Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study https://t.co/ilNcPYdV8U (@rschilsky)

Check out Dr. Virginia Kaklamani @VKaklamani @UTHealthSAMDA discussing #ASCO23 Oral #Elacestrant vs. SOC in ER+/HER2- Advanced or #mBC w/o Detectable #ESR1 Mutation (EMERALD) - Subgroup Analysis by Prior Duration of CDK4/6i + ET #bcsm #breastcancer #cdk46 https://t.co/SDTuK9Jxot (@Sameh_VuMedi)

Findings from a subgroup analysis of the phase 3 EMERALD trial demonstrated elacestrant elicited prolonged PFS vs SOC in ER+, HER2– non-detected ESR1 mutated breast cancer who experienced disease progression. @VKaklamani @ASCO #ASCO23 #bcsm https://t.co/IDnlmEDmWA (@OncLive)

ELAINE-2 study (N 29), all post CDK4/6i, ESR1-mutated selected HR+HER2- #bcsm lasofoxifene + abema ORR 55.6%, mPFS 56 weeks 💪. ELAINE 3 (NCT05696626) will compare LAS/Abema with Fulv/Abema. Watch out for dvt risk (N 3/29). #ASCO23 #postcdk46 (@antgiorda)

Enhertu made by @AstraZeneca who not yet involved in DETERMINE. There is an arm for HER2 mutated/ amplified using trastuzumab/pertuzumab. As Enhertu approved FDA should be evaluated by @MHRAgovuk and @NICEComms through project orbis. Need to ensure Her2 on test directory #lcsm (@AlastairGreyst2)

@ASCO recommends testing for #ESR1 mutations in ER+/HER2- MBC recurrent or progressed on ET. https://t.co/CiHKBfAE9i @ColumbiaRadOnc/@columbiacancer recently showed ESR1 mutations in 14.3% of HR+ MBC and 12% of pre-treated HR+ primary BC. (@RadOncConnor)

#ASCODailyNews highlights our rapid guideline update that provides new testing/treatment recommendations for pts w/ ER+, HER2- metastatic #breastcancer w/ ESR1 mutations: https://t.co/YlrRLXdh1l @AngieDemichele #bcsm (@ASCO)

Thankyou so much for taking the time to respond. This has given me hope. Just started a t&t trial. I’m mCRC with HER2 mutation. Will keep you updated on its success. (@tokyowaz)

@DrRiyazShah Hi Riyaz, You were suggested to us as a leader in lung cancer and we could really do with your help, my mum has HER2 mutation in her cancer and we are fighting to get her the right treatment. Can I email you? Thank you, Ellie (@elliely39073921)

😉No it's not #TumorBoardTuesday but I have a🧬molecular❓to ask you all😀 👉Patient with metastatic gastric cancer whose disease progressed on FOLFOX + nivo is found to have a🌟Gain of Function (Activating)🌟ERBB2 mutation ➡️No HER2⬆️by IHC🔬 🤔Would you try (inc. off label): (@MPishvaian)

Congratulations! We've published 2 articles showing a high prevalence of EGFR and ERBB2 mutations in lung adenos from patients bearing TP53 R337H, a Li-Fraumeni's founder mutation highly prevalent in South/ Southeast Brazil. 10.1016/j.cllc.2019.11.012 and 10.1111/1759-7714.13777 (@ClaudioVladmir)

Sorry, the approval doesn’t use “locally.” “postmenopausal women or adult men, w ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer w disease progression following at least 1 line of endocrine therapy.” These “advanced” definitions are still confusing though! (@itsnot_pink)

Just published! Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study https://t.co/GeWgWqTgV7 (@rschilsky)

Dr. @Latinamd with a fabulous comprehensive talk on treatment strategies for HER2-mutated NSCLC at #TexasLung23. ADCs and next generation TKIs are leading the way and excited to see further evolution in this space. @TLCconference (@Joshua_Reuss)

Outstanding presentation on HER2 mutation in NSCLC by my esteemed colleague from UM. Moving forward the bar with DESTINY-Lung 03 and -04 trials. @TLCconference @Latinamd @GenesisCareUS #TexasLung23 @edgardo_ny (@EdgardoSantosMD)

Very nice review on therapeutics for HER2 mutated NSCLC by ⁦@APassaroMD⁩ #ELCC23. What a long way we have come since the first paper by ⁦@FedericoCappuz1⁩ in 2006 and our cohort @GautschiOliver⁩ ⁦@peters_solange⁩ ⁦@barlesi⁩ in 2013. (@JulienMazieres)

Amazing! We were just discussing using T-DXD for lung cancer and brain mets with HER2 mutation (worked also!) and all of the complexities of why drug works with mutations in lung cancer at molecular tumor board @Perlmutter_CC (@guildsman)

Poziotinib in Treatment-Naïve HER2 Ex 20 Mutations: ZENITH20-4- Ph2 @JTOonline - N=80 - ORR 39%; DCR 73%; mPFS 5.6m - TRAEs: rash 45% stomatitis, diarrhea 15% - ⬆️ORR 71% in G778_P780dupGS ➡️ FDA declined 2nd line approval in 2022 pending more data #lcsm https://t.co/6CuMFdBTPk (@Latinamd)

Dr. @benlevylungdoc with an update on #HER2 NSCLC (mutation, not amplification or overexpression). Approved targeted agent is T-DXd (trastuzumab deruxtecan), an antibody drug conjugate. Other ADCs in development include those targeting Trop2 (datopotamab, sacituzumab) #PLCClive23 (@StephenVLiu)

Olaparib significantly prolonged progression-free survival in BRCA-mutated, HER-2 negative metastatic breast cancer, particularly in first line patients https://t.co/K11ilS97aF #fondazionebonadonna #oncology #cancerreseach @BianchiniGP @CarmenCriscit @mauricallari (@FondazioneBona1)

🔥Therapeutic Implications of Oncogenic Missense HER2 (ERBB2) Mutations in #GastricAdenocarcinoma @JCOPO_ASCO https://t.co/DFgjlZNpCY 👏Excellent molecular tumorboard discussion 👉Know your🎯& know your💊! @myESMO @OncoAlert (@ArndtVogel)

Great comprehensive talk Frederique Penault Llorca on ILC #breastcancer lobular: pleomorphic ILC: freq LN+, high grade, high RS-21, freq HER2+ or mutation, E-cad neg., TP53 mut, @myBBCC @AUB_Lebanon @institut Jean Perrin @OncoAlert @ (@NagiSaghir)

Not a MedOnc, but I work on HER2 mutations for a living. I'd add neratinib+fulvestrant+trastuzumab for ER+/HER2- MBC with HER2 activating mutations (from ctDNA or tissue) post-progression on CDK4/6i, and nerat+trast for ER-/HER2- HER2-mut MBC, maybe 2L. currently NCCN 2B (@AriellaHanker)

FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer https://t.co/71FQBY1D4U via @onclive (@DrFaridSaleh)

Elacestrant (345 mg taken orally with food once daily) approved for ER+ve, HER2-ve, ESR1-mutated advanced or metastatic breast cancer based on EMERALD trial https://t.co/0ZF6hLUvgu (@drkpavithran)

JUST OUT @US_FDA 🇺🇸Approves elacestrant in postmenopausal women/adult men w/ER➕HER2➖ESR1🧬mutated advanced or metastatic #BreastCancer w/disease progression following at least 1️⃣line ET Decision based on Efficacy in EMERALD💎 @OncoAlert 🚨@FDAOncology https://t.co/B0cTY6nN11 (@weoncologists)

The oral SERD Elacestrant is now approved for ESR1 mutated HR+/HER2- advanced #breastcancer after one line of ET, based on the results of the #EMERALD study🎯 One more option for our patients! (@ElisaAgostinett)

Should people with HR+, HER2- MBC be tested for ESR1 mutation on diagnosis, or only after progression on endocrine therapy? EMERALD was a fairly small study, but do you know if there was any analysis of which ESR1 mutations most people had? (@stage4kelly)

FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer https://t.co/qnNCx6fZmH via @onclive (@DrBonillaOnc)

Elacestrant (Orserdu) FDA approved for ER+ HER2- metastatic #breastcancer with #ESR1 mutation @OncoAlert #bcsm https://t.co/FV8dsW3Nxc (@JAMouabbi)

Besides HER2 mutations we should analyze HER2 expression in #NSCLC as a potential target for T-DXd. @OncoAlert Some trials ongoing here @CHUdeToulouse @crctoncopole (@JulienMazieres)

Today at #SABCS22, @hoperugo presents long term disease control data from a Phase II trial after CDK4/6i treatment in patients with the PIK3CA driver mutation in HR+/HER2- Advanced #BreastCancer. Abstract PD13-06 https://t.co/VU0I0z6Tmt (@NovartisOncMed)

📝Resistance mechanisms in HER2 mutated #breast cancers 🧐Potential use of microbiome in combinatorial immunotherapies to treat breast cancer tumour for effective response Full text: https://t.co/AtPKWE00r6 @BreastCancerNow @Liz_ORiordan @imtryam @JenRicher3 @TBJulianMD (@cdrjournal)

#Translational #oncology #research exploring ERBB2 gene🧬 mutations in patients with non-small cell lung cancers and clinicopathological characteristics related to the presence of #ERBB2 mutations 🔗https://t.co/2Grz6JLGUy @esinghimd #NSCLC (@TumoriJ)

My fellow #3MusketeersforLCSM presents a very interesting case on “Concomitant EGFR exon 19 deletion and ERBB2 mutation in a patient with metastatic non-small cell lung cancer” #EGFRSummit22 #lcsm @EGFRSummit @EGFRResisters (@esinghimd)

🔥Trastuzumab + FOLFOX for HER2+ biliary tract cancer🔥 @LancetGastroHep https://t.co/olurYdJedK 👉more options of 🎯💊in #CCA 👉MyPathway, HERB, ZW25, SUMMIT & now KCSG-HB19–14 ✅#CCA: Her2 mutations, amplifications & overexpression❗️ @myESMO @OncoAlert @EASLnews (@ArndtVogel)

Breaking down data in #colorectalcancer including #ctDNA @ajgoblue15⁩ with ⁦@OncoThor⁩ when to use it and how ⁦@OncLive⁩ ⁦@OncLiveSOSS⁩ #her2+ tx options are promising. #braf mutations more prominent in about 10% of metastatic #crc. Egfr with braf inhibit (@donnashort)

Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study https://t.co/HA285abNdj How was ERBB2 amplification defined? cc: @rschilsky @LGM_Biostats (@rsm2800)

Lobular #BreastCancer is molecularly different from IDC. #ctDNA mutations in CDH1, ERBB2, PTEN were associated with ILC. Similarly, CDH1 was co-mutated with PIK3CA, ERBB2 and ET resistance alterations in a cohort of ~7000 #MBC patients #bcsm #LiquidBiopsy https://t.co/Tx2fmuhug3 (@LGerratana)

Lobular #BreastCancer was associated with #ctDNA mutations in CDH1, ERBB2 and PTEN. Similarly, in an independent cohort of ~7000 #MBC patients, CDH1 was co-mutated with targetable (PIK3CA, ERBB2) and endocrine resistance alterations. #bcsm #LiquidBiopsy https://t.co/Tx2fmuhug3 (@LGerratana)